INVESTORS & MEDIA
Events & Presentations
The 2024 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. will be held on Friday, June 14, 2024, commencing at 10:30 a.m., Eastern Time, virtually via the Internet at www.virtualshareholdermeeting.com/REGN2024.
These slides contain the 60-week and 2-year (96-weeks) results from the Phase 3 PULSAR study of aflibercept 8 mg for nAMD. The presentation was given by Dr. Paolo Lanzetta at the 23rd EURETINA Congress on October 5, 2023.
These slides contain the 2-year (96 weeks) results from the Phase 2/3 PHOTON study of aflibercept 8 mg for DME. The presentation was given by Diana V. Do, MD at the American Society of Retina Specialists Annual Meeting on July 29, 2023.
The 2023 Annual Meeting of Shareholders of Regeneron Pharmaceuticals, Inc. will be held on Friday, June 9, 2023, commencing at 10:30 a.m., Eastern Time, virtually via the Internet at www.virtualshareholdermeeting.com/REGN2023.